Copyright
©The Author(s) 2020.
World J Gastroenterol. Oct 21, 2020; 26(39): 6027-6036
Published online Oct 21, 2020. doi: 10.3748/wjg.v26.i39.6027
Published online Oct 21, 2020. doi: 10.3748/wjg.v26.i39.6027
Table 3 Multivariable Cox regression analysis for overall survival
| Hazard ratio (95%CI) | P value | |
| Gender (male vs female) | 1.07 (0.77-1.48) | 0.69 |
| Baseline ECOG (continuous) | 1.33 (1.02-1.73) | 0.04 |
| Recurrent disease (vs de novo) | 0.86 (0.62-1.19) | 0.37 |
| Duration of first-line treatment | 1.00 (1.00-1.002) | 0.09 |
| Lines of treatment | 0.61 (0.50-0.74) | < 0.01 |
- Citation: Tsang ES, Lim HJ, Renouf DJ, Davies JM, Loree JM, Gill S. Real-world treatment attrition rates in advanced esophagogastric cancer. World J Gastroenterol 2020; 26(39): 6027-6036
- URL: https://www.wjgnet.com/1007-9327/full/v26/i39/6027.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i39.6027